Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive News Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Date Posted: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with dedicated mechanisms. Fortunately, several promising treatments have shown considerable potential—and with that, the possibility of significant sales. Two smaller biotech companies are experiencing notable share-price momentum thanks to their leading oncology drugs. Besides offering powerful treatment potential, these medicines could help the firms move beyond penny-stock or otherwise unstable status and toward long-term profitability. That said, both companies still face meaningful challenges, making these typical biotech investments high-risk ventures that could generate outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. That added to IOVA's year-to-date (YTD) performance, which has seen shares more than double. Still, with a consensus price target of $8.88, Wall Street expects more from IOVA shares—that target implies another roughly 71% upside from current levels. The main catalyst for Iovance's rally is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States for melanoma since 2024 and is gaining momentum both in sales and in regulatory progress, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Amtagvi's broader potential may lie outside melanoma: the drug received Fast Track designation from the FDA for the treatment of non-small cell lung cancer and could be effective against other tumor types as well. Some of Iovance's outperformance this year can also be attributed to its Q4 2025 earnings report, issued in late February, in which the company posted better-than-expected losses per share and $5 million in revenue. For the full year, revenue rose about 30% year-over-year (YOY). Iovance is still a penny stock and a relatively small (~$2 billion market-cap) biotech, and despite the recent rally analysts remain cautious: about half of its roughly dozen analyst ratings are Hold or Sell. Beyond the normal risks faced by smaller biotech firms, Iovance's manufacturing process for Amtagvi is a vulnerability. The therapy is personalized, costly, and complex to produce, which could limit profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug While ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year-to-date performance dwarfs that of many peers. IBRX shares are up nearly 300% in 2026 alone, and this could be just the beginning. Analysts have set a price target of $13.60, roughly 70% higher than the stock's current price even after the major rally. ImmunityBio's leading product and primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the EU regulator granted the drug conditional marketing authorization, the latest in a series of approvals worldwide. Anktiva's popularity is translating into revenue: the drug generated $113 million in sales last year, a roughly 700% YOY increase. Like Amtagvi, Anktiva may have potential in additional cancer indications, and ImmunityBio is actively exploring broader applications. Despite the surge over the past several quarters, IBRX remains a speculative and risky investment. IBRX posted a sizable full-year net loss of $351 million for 2025 as R&D expenses mounted. Still, Wall Street sentiment is comparatively bullish: six of seven analysts covering the stock rate it a Buy or equivalent. | 
